About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Liver Disease Clinical Trials | 203 Studies Recruiting

Clinical TrialsLiver Disease

Liver Disease Clinical Trials

Browse 203 clinical trials for liver disease. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 21-40 of 203 trials

TerminatedSafety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)The primary objective of this study is to evaluate whether SIM (formerly referred to as GS-6624) is effective at preventing the histologic progression of liver fibrosis and the…NCT01672866·Phoenix, Arizona and 67 others

Related Searches

cirrhosistrials nafldtrials

Data from ClinicalTrials.govTerms

TerminatedSimtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASHThe primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic…NCT01672879·Phoenix, Arizona and 58 others

CompletedStudy of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver FibrosisThe purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with…NCT03517540·Chandler, Arizona and 64 others

RecruitingAn Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic SteatosisHepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death.NCT05335603·Hvidovre

RecruitingRole of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With FibrosisThe purpose of the KETONASH study is to evaluate, in patients with metabolic-associated fatty liver disease (MAFLD) with non-alcoholic steatohepatitis (NASH) and significant liver…NCT06308757·Bologna

RecruitingEffect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLDOpen-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes…NCT05644717·Peshawar, KPK

Active not recruitingPrevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 DiabetesThe aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive…NCT04595474·Boston, Massachusetts

TerminatedMild Hypothermia and Acute Kidney Injury in Liver TransplantationAcute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies).NCT03534141·San Francisco, California and 2 others

Active not recruitingComparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With HyperuricemiaThis study aims at evaluating and comparing the protective outcomes of using Febuxostat versus Vitamin E in Hyperuricemia non-alcoholic steatohepatitis patients without cirrhosis.NCT05574036·Tanta

CompletedStudy Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisThe primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults…NCT03439254·Dothan, Alabama and 191 others

Recruiting"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test…NCT04690972·Strasbourg

Not yet recruitingWearable Patch Ultrasound Probe for Diagnosis of Liver StiffnessLiver stiffness measurement is a key non-invasive tool for assessing liver fibrosis and cirrhosis in patients with chronic liver disease.NCT07716384

CompletedProspective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLDHepatic steatosis and insulin resistance are associated with severity of fibrosis in non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C.NCT02031913·Seoul

RecruitingAutomated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek ProgrammeLiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in…NCT07658755·Madrid, Madrid

CompletedNon-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced FibrosisNon-alcoholic fatty liver disease (NAFLD) is defined as accumulation of fat in the liver which is not related to either alcohol excess or other causes such viral infection…NCT05485714·Al Ain City, Abu Dhabi Emirate

CompletedA Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver DamageSemaglutide is a medicine studied in patients with non-alcoholic steatohepatitis (NASH), as it may improve liver damage.NCT03987451·Chandler, Arizona and 37 others

TerminatedUtilization of MAsS in Patients Undergoing LT for HCCThe aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and…NCT05184283·New York, New York

CompletedUtilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver ProgressionNon-alcoholic fatty liver disease (NAFLD) is a common disorder, affecting \~30% of people in the general population and up to 96% of obese individuals.NCT02267148·Kannapolis, North Carolina

CompletedDasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver DiseaseTo examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled…NCT05506488·Amsterdam

RecruitingPROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic StudiesThe main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis…NCT04371042·Roma, Rome/lazio/italy

PreviousPage 2 of 11Next